methyl-phosphonic acid diallyl ester | 3479-32-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机膦酸及其衍生物
• 英文名称: methyl-phosphonic acid diallyl ester
• 英文别名: Methyl-phosphonsaeure-diallylester；methanephosphonic acid diallyl ester；Diallylmethylphosphonat；Phosphonic acid, methyl-, di-2-propenyl ester；3-[methyl(prop-2-enoxy)phosphoryl]oxyprop-1-ene
• CAS: 3479-32-1
• 化学式: C₇H₁₃O₃P
• 分子量: 176.152
• InChiKey: AFJASNIVRUSGMC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2931900090

反应信息

• 作为产物：
  描述：

  甲基膦酞二氯 、 烯丙醇 在 aluminum oxide 作用下， 以75%的产率得到methyl-phosphonic acid diallyl ester
  参考文献：
  名称：

  Acharya, Jyotiranjan; Shakya, Purushottam D.; Pardasani, Deepak, Journal of Chemical Research, 2005, # 3, p. 194 - 196

  摘要：

  DOI：

文献信息

• [EN] CENTRALLY ACTIVE AND ORALLY BIOAVAILABLE ANTIDOTES FOR ORGANOPHOSPHATE EXPOSURE AND METHODS FOR MAKING AND USING THEM<br/>[FR] ANTIDOTES CENTRALEMENT ACTIFS ET BIO-DISPONIBLES PAR VOIE ORALE UTILISABLES EN CAS D'EXPOSITION AUX ORGANOPHOSPHATES ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：UNIV CALIFORNIA

  公开号：WO2014127315A1

  公开（公告）日：2014-08-21

  In alternative embodiments, the invention provides nucleophilic hydroxyimino- acetamido alkylamine antidotes that cross the blood-brain barrier (BBB) to catalyze the hydrolysis of organophosphate (OP)-inhibited human acetylcholinesterase (hAChE) in the central nerve system (CNS). The hydroxyimino-acetamido alkylamines of the invention are designed to fit within AChE active center gorge dimensions, bind with reasonable affinity, and react with the conjugated phosphate atom in the gorge. The hydroxyimino- acetamido alkylamines of the invention are also designed to possess ionization states that govern affinity and reactivity for the two linked hAChE re-activation steps. In alternative embodiments, the invention provides pumps, devices, subcutaneous infusion devices, continuous subcutaneous infusion devices, infusion pens, needles, reservoirs, ampoules, a vial, a syringe, a cartridge, a disposable pen or jet injector, a prefilled pen or a syringe or a cartridge, a cartridge or a disposable pen or jet injector, a two chambered or multi- chambered pump, a syringe, a cartridge or a pen or a jet injector, comprising a compound of the invention.

  在另一种实施方式中，该发明提供了能够穿过血脑屏障（BBB）的亲核羟亚胺-乙酰胺基烷胺解毒剂，用于催化有机磷（OP）抑制的人类乙酰胆碱酯酶（hAChE）在中枢神经系统（CNS）中的水解。该发明的羟亚胺-乙酰胺基烷胺设计成适合AChE活性中心峡谷尺寸，具有合理的亲和力，并与峡谷中的共轭磷原子发生反应。该发明的羟亚胺-乙酰胺基烷胺还设计成具有调控两个连接的hAChE重新激活步骤的亲和力和反应性的电离态。在另一种实施方式中，该发明提供了泵、装置、皮下输注装置、连续皮下输注装置、输注笔、针头、储液器、安瓿、小瓶、注射器、笔式注射器或喷射器、预装笔或注射器或装置、装置或一次性笔或喷射器、两室或多室泵、注射器、装置或笔或喷射器，其中包括该发明的化合物。
• [EN] DERIVATIZATION OF RADIOPHARMACEUTICALS<br/>[FR] DÉRIVATION D'AGENTS RADIOPHARMACEUTIQUES
  申请人：BAYER PHARMA AG

  公开号：WO2012104225A1

  公开（公告）日：2012-08-09

  This invention relates to methods for analyzing radiopharmaceuticals wherein the radiopharmaceutical is derivatized beforehand. This method is suitable for compounds labeled with radioisotope or with cold counterpart e.g. 18F or 19F, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for analyzing radiopharmaceuticals. wherein R1 is C(=0)OR6; R2 is C(=0)OR7; R3 is,19F or 18F R4 is hydrogen, Methyl, Ethyl, Propyl. Butyl, t-Butyl or Benzyl; R5 is hydrogen. Methyl, Ethyl, Propyl. Butyl, t-Butyl or Benzyl; R6 is hydrogen, Methyl, Ethyl, Propyl, Butyl, t-Butyl or Benzyl; R7 is hydrogen, Methyl, Ethyl, Propyl. Butyl, t-Butyl or Benzyl; with the proviso that at least one of R4, R5, R6, and R7 is hydrogen

  本发明涉及分析放射性药物的方法，其中预先对放射性药物进行衍生化。该方法适用于标记有放射性同位素或冷对应物的化合物，例如18F或19F，包括此类化合物的组合物、包含此类化合物或组合物的试剂盒以及用于分析放射性药物的此类化合物、组合物或试剂盒的用途。其中R1为C(=0)OR6；R2为C(=0)OR7；R3是19F或18F；R4为氢、甲基、乙基、丙基、丁基、叔丁基或苄基；R5为氢、甲基、乙基、丙基、丁基、叔丁基或苄基；R6为氢、甲基、乙基、丙基、丁基、叔丁基或苄基；R7为氢、甲基、乙基、丙基、丁基、叔丁基或苄基；但至少有一个R4、R5、R6和R7为氢。
• [EN] HETEROAROMATIC ELECTROPHILES AND METHODS OF USING THEREOF<br/>[FR] ÉLECTROPHILES HÉTÉROAROMATIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：OHIO STATE INNOVATION FOUNDATION

  公开号：WO2018152329A1

  公开（公告）日：2018-08-23

  Disclosed herein are compounds, compositions, and methods for reactivating or realkylating aged acetylcholinesterase inhibited by or conjugated to the organophosphorus compound. The organophosphorus compound can be a nerve agent. The acetylcholinesterase can be in the central nerve system (CNS) and/or the peripheral nervous system (PNS) of a subject. Accordingly, methods for ameliorating, diminishing, reversing, treating or preventing the toxic effects of an organophosphorus compound in a subject are provided herein. Methods for prophylactic or therapeutic treatment of exposure to an organophosphorus nerve agent are also provided.

  本文揭示了一种化合物、组合物和方法，用于重新激活或重新烷基化被有机磷化合物抑制或结合的老化乙酰胆碱酯酶。有机磷化合物可以是神经毒剂。乙酰胆碱酯酶可以存在于受试者的中枢神经系统（CNS）和/或外周神经系统（PNS）。因此，本文提供了用于改善、减轻、逆转、治疗或预防受试者中有机磷化合物毒性影响的方法。还提供了用于预防或治疗暴露于有机磷神经毒剂的方法。
• ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE
  申请人：DAIKIN INDUSTRIES, LTD.

  公开号：US20200280096A1

  公开（公告）日：2020-09-03

  An electrolyte solution containing a compound represented by the following formula (1): wherein R 101 and R 102 are the same as or different from each other and are each a hydrogen atom, a fluorine atom, or an alkyl group optionally containing a fluorine atom; and R 103 is an alkyl group or an organic group containing an unsaturated carbon-carbon bond. Also disclosed is an electrochemical device and lithium ion secondary battery including the electrolyte solution, and a module including the electrochemical device or lithium ion secondary battery.

  一种电解质溶液，包含由以下化学式（1）表示的化合物：其中R101和R102彼此相同或不同，分别为氢原子、氟原子或含有氟原子的烷基基团；R103为烷基基团或含有不饱和碳-碳键的有机基团。还公开了包括该电解质溶液的电化学器件和锂离子二次电池，以及包括电化学器件或锂离子二次电池的模块。
• [EN] CENTRALLY ACTIVE AND ORALLY BIOAVAILABLE UNCHARGED BISOXIME ANTIDOTES FOR ORGANOPHOSPHATE POISONING AND METHODS FOR MAKING AND USING THEM<br/>[FR] ANTIDOTES DE BISOXIME NON CHARGÉS À ACTIVITE CENTRALE ET BIODISPONIBILITE ORALE CONTRE L'INTOXICATION AUX ORGANOPHOSPHATES ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：UNIV CALIFORNIA

  公开号：WO2020237079A1

  公开（公告）日：2020-11-26

  In alternative embodiments, provided are uncharged bis-oxime antidotes that cross the blood-brain barrier (BBB) to catalyze the hydrolysis of organophosphate (OP)-inhibited human acetylcholinesterase (hAChE) in the central nerve system (CNS). In alternative embodiments, provided are pumps, devices, subcutaneous infusion devices, continuous subcutaneous infusion devices, infusion pens, needles, reservoirs, ampoules, a vial, a syringe, a cartridge, a disposable pen or jet injector, a prefilled pen or a syringe or a cartridge, a cartridge or a disposable pen or jet injector, a two chambered or multi-chambered pump, a syringe, a cartridge or a pen or a jet injector, comprising a compound as provided herein.

  在另一种实施方式中，提供了穿越血脑屏障（BBB）的未带电双肟解毒剂，用于催化有机磷酸酯（OP）抑制的人体乙酰胆碱酯酶（hAChE）在中枢神经系统（CNS）中的水解。在另一种实施方式中，提供了泵、设备、皮下输液装置、连续皮下输液装置、输液笔、针头、储液器、安瓿、小瓶、注射器、笔式注射器或喷射器、预充式笔或注射器或卡匣、卡匣或一次性笔或喷射器、双室或多室泵、注射器、卡匣或笔或喷射器，包括本文提供的化合物。